1. Home
  2. ELTK vs ALXO Comparison

ELTK vs ALXO Comparison

Compare ELTK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eltek Ltd.

ELTK

Eltek Ltd.

HOLD

Current Price

$9.20

Market Cap

61.5M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.38

Market Cap

68.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELTK
ALXO
Founded
1970
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.5M
68.3M
IPO Year
1997
2020

Fundamental Metrics

Financial Performance
Metric
ELTK
ALXO
Price
$9.20
$2.38
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$3.42
AVG Volume (30 Days)
3.1K
579.5K
Earning Date
03-10-2026
03-05-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
N/A
EPS
0.17
N/A
Revenue
$49,310,000.00
N/A
Revenue This Year
$18.60
N/A
Revenue Next Year
$9.04
N/A
P/E Ratio
$49.00
N/A
Revenue Growth
2.54
N/A
52 Week Low
$7.65
$0.40
52 Week High
$12.19
$2.41

Technical Indicators

Market Signals
Indicator
ELTK
ALXO
Relative Strength Index (RSI) 55.81 77.38
Support Level $8.55 $1.36
Resistance Level $9.10 $2.41
Average True Range (ATR) 0.47 0.23
MACD 0.00 0.09
Stochastic Oscillator 81.47 95.92

Price Performance

Historical Comparison
ELTK
ALXO

About ELTK Eltek Ltd.

Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: